• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Lee Landenberger

Articles by Lee Landenberger

Kronos makes time for series A financing, adds $105M with help from execs, board members

July 19, 2019
By Lee Landenberger
Kronos Bio Inc. closed a $105 million series A preferred stock financing, shored up by a board composed of longtime pharma executives that includes the company CEO and president, Norbert Bischofberger, the former Gilead Sciences Inc. R&D executive vice president and chief science officer.
Read More

Astellas, Frequency in worldwide agreement targeting hearing loss

July 18, 2019
By Lee Landenberger
Astellas Pharma Inc. and Frequency Therapeutics Inc. have agreed to develop and commercialize Frequency's regenerative therapeutic candidate, FX-322, to treat sensorineural hearing loss (SNHL).
Read More

Macrogenics, I-Mab ink enoblituzumab collaboration targeting greater China

July 17, 2019
By Lee Landenberger
Macrogenics Inc. is taking a further step into Asia as it joins with I-Mab Biopharma (Shanghai) Co. Ltd. in a collaboration and license agreement to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody.
Read More

Convelo, Genentech ink remyelinating therapies alliance

July 17, 2019
By Lee Landenberger
Rising from Case Western Reserve in Cleveland was science that Roche Holding AG's Genentech Inc. could not pass up, so it struck a deal with Convelo Therapeutics Inc. to discover and develop remyelinating medicines for patients with neurological disorders such as multiple sclerosis.
Read More

Recursion closes on a $121M series C for AI-backed R&D

July 16, 2019
By Lee Landenberger
Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.
Read More

Macrogenics, I-Mab ink enoblituzumab greater China deal

July 12, 2019
By Lee Landenberger
Macrogenics Inc. is taking a further step into Asia as it joins with I-Mab Biopharma (Shanghai) Co. Ltd. in a collaboration and license agreement to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody.
Read More

Jazz deal seeks to move Redx out of red, into black

July 11, 2019
By Lee Landenberger
Jazz Pharmaceuticals plc's acquisition of Redx Pharma plc's pan-RAF inhibitor program for treating RAF- and RAS-mutant tumors was rocket fuel for Redx's stock (AIM:REDX), which closed 108% higher than it opened, offering some relief for the struggling company.
Read More

Altimmune acquires Velocity's Spitfire and its NASH candidate

July 10, 2019
By Lee Landenberger
Altimmune Inc. will acquire Spitfire Pharma Inc. and its lead candidate, SP-1373 (to be renamed ALT-801), a GLP-1/glucagon receptor co-agonist for treating nonalcoholic steatohepatitis (NASH).
Read More

Mixed clinical news for Intra-Cellular is bad news for stock

July 9, 2019
By Lee Landenberger
Positive data from one clinical trial evaluating lumateperone in patients with bipolar disorder wasn't enough to lift Intra-Cellular Therapies Inc.'s stock Monday as another trial's failure with the same drug severely dampened the price of shares, while analysts took the long, more optimistic view.
Read More

FDA halts Unum's phase I trial again due to safety concerns

July 5, 2019
By Lee Landenberger
The FDA placed a clinical hold Wednesday on a phase I trial by Unum Therapeutics Inc. after a patient experienced serious adverse events that included grade 3 neurotoxicity and cytomegalovirus infection, and grade 4 respiratory distress.
Read More
Previous 1 2 … 136 137 138 139 140 141 142 143 144 … 147 148 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 17, 2025.
  • Multiple myeloma and antibodies

    Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

    BioWorld
    The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
  • Atai Therapeutics discovers new 5-HT2A receptor partial agonists

    BioWorld Science
    Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...
  • PHD inhibitors reported in Akebia Therapeutics patent

    BioWorld Science
    Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe